Frontal fibrosing alopecia (FFA) is a form of scarring hair loss that primarily affects the frontal and temporal hairline. First described by Kossard in 1994, it was initially considered rare. In the decades since, reported cases have increased dramatically, prompting some dermatologists to describe it as an emerging epidemic. FFA predominantly affects postmenopausal women, though premenopausal women and men can also develop it. Unlike androgenetic alopecia, where follicles miniaturize but survive, FFA destroys follicles permanently through lymphocytic inflammation and fibrosis. Early detection is critical because once a follicle is scarred, no treatment can restore it. BaldingAI tracking can capture progressive hairline recession over weeks and months, producing visual evidence that prompts earlier dermatology referral when something beyond normal thinning is occurring.
TL;DR
- Frontal fibrosing alopecia is a lymphocytic cicatricial (scarring) alopecia that causes progressive, permanent hairline recession.
- Key signs include band-like hairline recession, eyebrow thinning or loss, perifollicular erythema, and the “lonely hair sign” (isolated terminal hairs in the frontal band).
- FFA differs from androgenetic alopecia in that it destroys follicles through scarring rather than shrinking them through miniaturization.
- Treatment focuses on halting progression: hydroxychloroquine, 5-alpha reductase inhibitors (finasteride, dutasteride), and topical tacrolimus are the most commonly used agents.
- Since scarring is irreversible, the goal is early diagnosis and intervention before extensive follicle loss.
Important
This article is educational and not medical advice. If you are worried about sudden shedding, scalp symptoms, or side effects, talk to a licensed clinician.
What is frontal fibrosing alopecia?
FFA belongs to a family of conditions called primary cicatricial (scarring) alopecias, specifically the lymphocytic subgroup. It is now widely considered a clinical variant of lichen planopilaris (LPP), sharing the same histopathological pattern: a lichenoid lymphocytic infiltrate that targets the bulge region of the hair follicle, where the stem cells that regenerate the follicle reside. When those stem cells are destroyed by the inflammatory process, the follicle is replaced by fibrous scar tissue and can never produce hair again.
What distinguishes FFA from classic LPP is its characteristic pattern. FFA selectively affects the frontotemporal hairline, producing a symmetrical, band-like recession that moves progressively posteriorly. The recession pattern is distinct from androgenetic alopecia: instead of gradual thinning with miniaturized hairs visible throughout the transition zone, FFA creates a sharp, scar-like border with bare, smooth skin in front and normal-density hair behind.
Kossard and Zagarella (1997) published the first case series of 16 postmenopausal women, all presenting with progressive frontal hairline recession, perifollicular erythema, and eyebrow loss. Since then, prevalence studies suggest FFA may have increased by a factor of ten or more since the 1990s. A 2019 systematic review by Lobato-Berezo et al. in the Journal of the American Academy of Dermatology analyzed 932 published cases and confirmed that 83% of FFA patients are postmenopausal women, with a mean age of onset around 56 years.
Recognizing the signs
The hallmark symptom of FFA is progressive recession of the frontal hairline in a band-like pattern. The recession typically affects the entire frontal hairline from temple to temple, though it may be more pronounced laterally. The skin in the affected zone appears pale, shiny, and smooth, reflecting the underlying scarring. Some patients notice that their forehead has become “taller” over time, which is the recession redefining the facial proportions.
Eyebrow loss is present in 50 to 80% of FFA cases, according to multiple cohort studies, and in some patients it precedes the scalp involvement by months or years. The eyebrow thinning is typically bilateral and affects the lateral portion first, progressing medially. Eyelash loss, while less common, occurs in approximately 10 to 15% of cases.
On close inspection (or trichoscopy), the active edge of FFA shows perifollicular erythema: a ring of redness around individual follicles at the advancing border. This perifollicular redness indicates active inflammation and distinguishes FFA from a stable, burned-out scar. Perifollicular scaling may also be visible, appearing as small, whitish tubular casts around hair shafts.
The “lonely hair sign,” first described by Tosti et al., refers to isolated terminal hairs remaining in the frontal band of recession. These stranded hairs are surrounded by bare, scarred skin and are themselves in the process of being lost. Their presence is a trichoscopic clue that the recession is active and ongoing.
How FFA differs from androgenetic alopecia
The distinction between FFA and female pattern hair loss (androgenetic alopecia in women) is clinically critical because the prognosis and treatment approach differ substantially.
In androgenetic alopecia, follicles undergo miniaturization: they progressively shrink under the influence of dihydrotestosterone (DHT) and produce thinner, shorter hairs with each cycle. The follicle itself survives. Treatment with anti-androgens or minoxidil can halt and sometimes reverse the process because the follicular structure remains intact.
In FFA, the follicle is destroyed. The lymphocytic infiltrate attacks the isthmus and infundibulum of the follicle, destroying the bulge stem cell population. This triggers a fibrotic replacement: the follicle is literally replaced by scar tissue. There is no miniaturized hair emerging from a shrinking follicle. There is no follicle at all. Once this process is complete in a given follicle, the loss is permanent. No medication, topical treatment, or procedure can regenerate a scarred follicle with current technology.
Clinically, the pattern also differs. Androgenetic alopecia in women typically causes diffuse thinning over the central scalp (Ludwig pattern), preserving the frontal hairline. FFA specifically targets the frontal hairline and may spare the central scalp entirely. That said, some patients have both conditions simultaneously, which can complicate diagnosis. A scalp biopsy with horizontal sectioning is definitive: FFA shows lichenoid inflammation around the follicular isthmus with concentric perifollicular fibrosis, while androgenetic alopecia shows follicular miniaturization without scarring.
Diagnostic criteria
There is no single diagnostic test for FFA. Diagnosis is based on a combination of clinical presentation, trichoscopic findings, and histopathology. The diagnostic criteria proposed by Vano-Galvan et al. (2014) include: progressive recession of the frontotemporal hairline, absence of follicular openings in the affected zone (indicating scarring), perifollicular erythema or scaling at the active margin, and histological confirmation of lichenoid interface dermatitis targeting the follicular isthmus.
A pull test at the active edge of the recession may yield positive results (easy detachment of hairs), indicating active inflammation. Trichoscopic features include loss of follicular openings, perifollicular erythema, perifollicular scaling, lonely hairs, and absence of the vellus hairs that would be expected in androgenetic alopecia. The combination of hairline recession plus eyebrow loss in a postmenopausal woman is considered highly suggestive of FFA even before biopsy.
If you notice a pattern of progressive hairline change that does not fit the typical diffuse thinning of androgenetic alopecia, or if you are losing eyebrow hair alongside scalp hair, that warrants a prompt dermatology referral. The distinction between FFA and androgenetic alopecia changes the urgency of treatment: androgenetic alopecia progresses slowly and allows time for decision-making, while FFA destroys follicles in real time.
Treatment options
There is no FDA-approved treatment specifically for FFA, and no treatment has been shown to regrow hair in scarred areas. The goal of all current therapies is to slow or halt the progression of the inflammatory process, preserving the follicles that remain.
Hydroxychloroquine (200 to 400 mg daily) is the most widely used first-line systemic treatment. Originally an antimalarial, it has immunomodulatory properties that suppress the lymphocytic infiltrate targeting follicles. A 2014 retrospective study by Vano-Galvan et al. in the Journal of the American Academy of Dermatology analyzed 355 FFA patients and found that hydroxychloroquine stabilized or improved the condition in approximately 60% of treated patients over a 12-month follow-up period.
5-alpha reductase inhibitors (finasteride 2.5 to 5 mg or dutasteride 0.5 mg daily) are used as monotherapy or in combination with hydroxychloroquine. The rationale is that androgens may play a permissive role in FFA pathogenesis, supported by the condition’s predilection for the androgen-sensitive frontotemporal hairline and its association with the postmenopausal hormonal shift. Finasteride has shown stabilization in multiple case series, and dutasteride (a more potent 5-alpha reductase inhibitor) has been reported as effective in patients who did not respond to finasteride.
Topical tacrolimus (0.1% ointment) is a calcineurin inhibitor that suppresses T-cell activation locally. It is applied directly to the active margin of the recession. While systemic absorption is minimal, it requires consistent daily application and may take three to six months to demonstrate effect. It is often used in combination with systemic therapy.
Other treatments reported in the literature include intralesional corticosteroid injections (triamcinolone acetonide into the active border), topical minoxidil (which does not address the scarring but may support remaining follicles), doxycycline, and pioglitazone. A 2021 review by Moreno-Arrones et al. in Dermatologic Therapy noted that combination regimens (systemic plus topical) tend to outperform monotherapy, though randomized controlled trial data is still lacking.
Why early detection matters more in FFA than in androgenetic alopecia
In androgenetic alopecia, the argument for early treatment is that miniaturized follicles respond better to intervention than severely miniaturized ones. But even in advanced cases, the follicles still exist, and some degree of improvement is often possible.
In FFA, there is no analogous safety net. Once a follicle is replaced by scar tissue, it is gone permanently. Treatment can only protect follicles that have not yet been scarred. The difference between starting treatment when 10% of frontal follicles have been destroyed versus 50% is the difference between a cosmetically acceptable outcome and a significantly altered hairline that can only be addressed with surgical techniques like hair transplantation.
This is where consistent photo tracking proves valuable. FFA progression can be subtle on a week-to-week basis, and patients often delay seeking care because they attribute the recession to normal aging or androgenetic alopecia. Comparing monthly or bimonthly photos with standardized positioning reveals the characteristic band-like recession pattern far earlier than occasional mirror checks. BaldingAI produces time-series data from your hairline scans, making it straightforward to document changes and present them to a dermatologist at the first appointment rather than trying to describe months of gradual change from memory.
The bottom line
Frontal fibrosing alopecia is not a benign condition that can be monitored indefinitely. It is an active, destructive process that permanently eliminates follicles. The increasing prevalence over the past two decades means clinicians and patients alike need to be familiar with its presentation: symmetric band-like frontal hairline recession, eyebrow loss, perifollicular erythema, and the absence of follicular openings in affected areas.
If your hairline is receding and you notice any of these features, do not assume it is standard pattern hair loss. Request a dermatological evaluation, ideally with a trichoscopy and biopsy if FFA is suspected. The treatments available (hydroxychloroquine, 5-alpha reductase inhibitors, topical tacrolimus) can slow or stop the process, but they cannot rebuild what has already been lost. The earlier you act, the more hair you keep.
Track your hairline changes over time
BaldingAI captures standardized hairline scans that reveal progressive changes, helping you build a visual timeline to share with your dermatologist.
Your scans stay private. Delete or export anytime.
Sources: Kossard & Zagarella 1997, Australasian Journal of Dermatology, Vano-Galvan et al. 2014, Journal of the American Academy of Dermatology, Lobato-Berezo et al. 2019, Journal of the American Academy of Dermatology.
